scholarly journals Secreted factors from metastatic prostate cancer cells stimulate mesenchymal stem cell transition to a pro-tumourigenic ‘activated’ state that enhances prostate cancer cell migration

2018 ◽  
Vol 142 (10) ◽  
pp. 2056-2067 ◽  
Author(s):  
Sarah M. Ridge ◽  
Dibyangana Bhattacharyya ◽  
Eoin Dervan ◽  
Serika D. Naicker ◽  
Amy J. Burke ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stem Cell ◽  
Cell Migration ◽  
Metastatic Prostate Cancer ◽  
Prostate Cancer Cell ◽  
Cancer Cell Migration ◽  
Prostate Cancer Cells ◽  
Secreted Factors ◽  
Activated State ◽  
Cell Transition

scholarly journals Tumor-associated Endo180 requires stromal-derived LOX to promote metastatic prostate cancer cell migration on human ECM surfaces

2015 ◽  
Vol 33 (2) ◽  
pp. 151-165 ◽  
Author(s):  
Matthew P. Caley ◽  
Helen King ◽  
Neel Shah ◽  
Kai Wang ◽  
Mercedes Rodriguez-Teja ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Migration ◽  
Cancer Cell ◽  
Metastatic Prostate Cancer ◽  
Prostate Cancer Cell ◽  
Cancer Cell Migration

scholarly journals Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Jeremy J. McGuire ◽  
Jeremy S. Frieling ◽  
Chen Hao Lo ◽  
Tao Li ◽  
Ayaz Muhammad ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cancer Cells ◽  
Metastatic Prostate Cancer ◽  
Prostate Cancer Cell ◽  
Prostate Cancer Cells ◽  
Interleukin 28 ◽  
Selection Of

AbstractBone metastatic prostate cancer (PCa) promotes mesenchymal stem cell (MSC) recruitment and their differentiation into osteoblasts. However, the effects of bone-marrow derived MSCs on PCa cells are less explored. Here, we report MSC-derived interleukin-28 (IL-28) triggers prostate cancer cell apoptosis via IL-28 receptor alpha (IL-28Rα)-STAT1 signaling. However, chronic exposure to MSCs drives the selection of prostate cancer cells that are resistant to IL-28-induced apoptosis and therapeutics such as docetaxel. Further, MSC-selected/IL-28-resistant prostate cancer cells grow at accelerated rates in bone. Acquired resistance to apoptosis is PCa cell intrinsic, and is associated with a shift in IL-28Rα signaling via STAT1 to STAT3. Notably, STAT3 ablation or inhibition impairs MSC-selected prostate cancer cell growth and survival. Thus, bone marrow MSCs drive the emergence of therapy-resistant bone metastatic prostate cancer yet this can be disabled by targeting STAT3.

scholarly journals Roles of the Na+/H+ Exchanger Isoform 1 and Urokinase in Prostate Cancer Cell Migration and Invasion

2021 ◽  
Vol 22 (24) ◽  
pp. 13263
Author(s):  
Xiuju Li ◽  
Benjamin Buckley ◽  
Konstantin Stoletov ◽  
Yang Jing ◽  
Marie Ranson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Migration ◽  
Cancer Cells ◽  
Cancer Cell ◽  
Colony Formation ◽  
Prostate Cancer Cell ◽  
Cancer Cell Migration ◽  
Prostate Cancer Cells

Prostate cancer is a leading cause of cancer-associated deaths in men over 60 years of age. Most patients are killed by tumor metastasis. Recent evidence has implicated a role of the tumor microenvironment and urokinase plasminogen activator (uPA) in cancer cell migration, invasion, and metastasis. Here, we examine the role of the Na+/H+ exchanger isoform 1 (NHE1) and uPA in DU 145 prostate cancer cell migration and colony formation. Knockout of NHE1 reduced cell migration. The effects of a series of novel NHE1/uPA hexamethylene-amiloride-based inhibitors with varying efficacy towards NHE1 and uPA were examined on prostate cancer cells. Inhibition of NHE1—alone, or with inhibitors combining NHE1 or uPA inhibition—generally did not prevent prostate cancer cell migration. However, uPA inhibition—but not NHE1 inhibition—prevented anchorage-dependent colony formation. Application of inhibitors at concentrations that only saturate uPA inhibition decreased tumor invasion in vivo. The results suggest that while knockout of NHE1 affects cell migration, these effects are not due to NHE1-dependent proton translocation. Additionally, while neither NHE1 nor uPA activity was critical in cell migration, only uPA activity appeared to be critical in anchorage-dependent colony formation of DU 145 prostate cancer cells and invasion in vivo.

scholarly journals Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells

2019 ◽  
Vol 8 (3) ◽  
pp. 354 ◽  
Author(s):  
Kouji Izumi ◽  
Atsushi Mizokami
Keyword(s):  
Prostate Cancer ◽  
Cell Migration ◽  
Androgen Receptor ◽  
Cancer Cells ◽  
Cancer Cell ◽  
Cancer Metastasis ◽  
Prostate Cancer Cell ◽  
Standard Form ◽  
Cancer Cell Migration ◽  
Prostate Cancer Cells

Androgen/androgen receptor (AR) signaling is a significant driver of prostate cancer progression, therefore androgen-deprivation therapy (ADT) is often used as a standard form of treatment for advanced and metastatic prostate cancer patients. However, after several years of ADT, prostate cancer progresses to castration-resistant prostate cancer (CRPC). Androgen/AR signaling is still considered an important factor for prostate cancer cell survival following CRPC progression, while recent studies have reported dichotomic roles for androgen/AR signaling. Androgen/AR signaling increases prostate cancer cell proliferation, while simultaneously inhibiting migration. As a result, ADT can induce prostate cancer metastasis. Several C-C motif ligand (CCL)-receptor (CCR) axes are involved in cancer cell migration related to blockade of androgen/AR signaling. The CCL2-CCR2 axis is negatively regulated by androgen/AR signaling, with the CCL22-CCR4 axis acting as a further downstream mediator, both of which promote prostate cancer cell migration. Furthermore, the CCL5-CCR5 axis inhibits androgen/AR signaling as an upstream mediator. CCL4 is involved in prostate carcinogenesis through macrophage AR signaling, while the CCL21-CCR7 axis in prostate cancer cells is activated by tumor necrotic factor, which is secreted when androgen/AR signaling is inhibited. Finally, the CCL2-CCR2 axis has recently been demonstrated to be a key contributor to cabazitaxel resistance in CRPC.

scholarly journals Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration

Oncogene ◽  
2003 ◽  
Vol 22 (10) ◽  
pp. 1475-1485 ◽  
Author(s):  
Jun-Wei Liu ◽  
Jian-Jun Shen ◽  
Angela Tanzillo-Swarts ◽  
Bobby Bhatia ◽  
Carlos M Maldonado ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Migration ◽  
Cancer Cells ◽  
Cancer Cell ◽  
Prostate Cancer Cell ◽  
Annexin Ii ◽  
Cancer Cell Migration ◽  
Prostate Cancer Cells

scholarly journals Novel lncRNA LINC00844 Regulates Prostate Cancer Cell Migration and Invasion through AR Signaling

2018 ◽  
Vol 16 (12) ◽  
pp. 1865-1878 ◽  
Author(s):  
Shreyas Lingadahalli ◽  
Sudhir Jadhao ◽  
Ying Ying Sung ◽  
Mi Chen ◽  
Lingling Hu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Migration ◽  
Cancer Cell ◽  
Prostate Cancer Cell ◽  
Migration And Invasion ◽  
Cancer Cell Migration ◽  
Cell Migration And Invasion
Sign in / Sign up

Export Citation Format

Share Document